Article

Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model

2024-03-05

Abstract excerpt

Neuroblastoma (NB) is a childhood cancer with heterogeneous characteristics, posing challenges to effective treatment. NBs express somatostatin receptors that facilitates the use of somatostatin analogs (SSTAs) as tumor-seeking agents for diagnosis and therapy. High-risk (HR) NBs often have gain-of-function mutations in the receptor tyrosine kinase anaplastic lymphoma kinase (ALK). Despite intensive multimodal tre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: faa750b0-f3e0-5a06-ad70-ca2858af440f
DOI: 10.20944/preprints202403.0251.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft ModelDOI 10.20944/preprints202403.0251.v1Read

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELSSemantic proximity Read

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.Semantic proximity Read

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsSemantic proximity Read

Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work BetterSemantic proximity Read

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHOSemantic proximity Read

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Semantic proximity Read

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1.Semantic proximity Read

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.Semantic proximity Read

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastomaSemantic proximity Read

New Developments in Peptide Receptor Radionuclide TherapySemantic proximity Read

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATESemantic proximity Read

The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131.Semantic proximity Read